PPA
OVID icon

Parametric Portfolio Associates’s Ovid Therapeutics OVID Stock Holding History

Parametric Portfolio Associates’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22,864
Closed -$89K – 3642
2021
Q2 		$89K Buy
+22,864
New +$90.2K ﹤0.01% 3497
2019
Q1 		– Sell
-10,580
Closed -$26K – 3958
2018
Q4 		$26K Buy
+10,580
New +$48.3K ﹤0.01% 3879

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Parametric Portfolio Associates's OVID Position: Q3 2021 in Review

Parametric Portfolio Associates sold out of Ovid Therapeutics (OVID) in Q3 2021, closing a stake of 22,864 shares — an estimated $89K sold.

Parametric Portfolio Associates first reported a position in OVID in Q4 2018 and held it in 2 quarters. The position peaked at $89K in Q2 2021. 72 funds tracked by Wall St. Rank hold OVID as of Q3 2021.

  • Parametric Portfolio Associates reported no remaining Ovid Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 22,864 Ovid Therapeutics shares in Q3 2021, an estimated $89K.
  • Parametric Portfolio Associates first reported a position in Ovid Therapeutics in Q4 2018 and held it in 2 quarters.
  • Parametric Portfolio Associates's Ovid Therapeutics position peaked at $89K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2021.

Based on Parametric Portfolio Associates's 13F filing for Q3 2021, filed 15 Nov 2021.